Trade

with

GTx Inc
(NASDAQ: GTXI)
AdChoices
0.6175
-0.0025
-0.40%
After Hours :
0.6500
+0.0325
+5.26%

Open

0.6700

Previous Close

0.6200

Volume (Avg)

94.25k (223.89k)

Day's Range

0.6100-0.6922

52Wk Range

0.4100-2.35

Market Cap.

47.13M

Dividend Rate ( Yield )

-

Beta

1.22

Shares Outstanding

76.01M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 0

    • Net Income

    • -42.11M

    • Market Cap.

    • 47.13M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.22

    • Forward P/E

    • -1.72

    • Price/Sales

    • -

    • Price/Book Value

    • 3.08

    • Price/Cash flow

    • -1.13

      • EBITDA

      • -43.22M

      • Return on Capital %

      • -139.32

      • Return on Equity %

      • -183.10

      • Return on Assets %

      • -139.32

      • Book Value/Share

      • 0.20

      • Shares Outstanding

      • 76.01M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 2.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.34

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 4.98

              • 2.92

              • Quick Ratio

              • 4.66

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.25

              • 2.21

              • Book Value/Share

              • 0.20

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.13

                • 277.78

                • P/E Ratio 5-Year High

                • -20.04

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.75

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.35

                • Price/Book Value

                • 3.08

                • 8.50

                • Price/Cash Flow Ratio

                • -1.13

                • 50.25

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -183.10

                    (-114.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -139.32

                    (-46.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -183.10

                    (-114.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -43.60M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.13
                  Ownership

                  Institutional Ownership

                  21.92%

                  Top 10 Institutions

                  23.61%

                  Mutual Fund Ownership

                  1.62%

                  Float

                  31.91%

                  5% / Insider Ownership

                  31.89%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    423,568

                  • 0.00

                  • 0.56

                  • Vanguard Extended Market Index Fund

                  •  

                    245,683

                  • 0.00

                  • 0.32

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    79,767

                  • 0.00

                  • 0.10

                  • iShares Micro-Cap

                  •  

                    76,996

                  • 1.28

                  • 0.09

                  • BlackRock Small Cap Growth Equity Port

                  •  

                    73,283

                  • 0.00

                  • 0.10

                  • Vanguard Instl Total Stock Market Index

                  •  

                    69,694

                  • 0.00

                  • 0.09

                  • EB DL Non-SL Market Completion Fund

                  •  

                    28,870

                  • 526.93

                  • 0.04

                  • The Vanguard - Total Stk Mkt Idx Trust. CF

                  •  

                    25,450

                  • 0.00

                  • 0.03

                  • BlackRock Master Small Cap Growth Port

                  •  

                    22,242

                  • 0.00

                  • 0.03

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Schuler Family Foundation

                  •  

                    6,266,954

                  • +36.49%

                  • 9.92

                  • BlackRock Fund Advisors

                  •  

                    1,428,697

                  • -4.13%

                  • 1.88

                  • Vanguard Group, Inc.

                  •  

                    709,413

                  • -3.58%

                  • 0.93

                  • Northern Trust Investments, N.A.

                  •  

                    285,519

                  • -20.20%

                  • 0.38

                  • Oracle Investment Management Inc

                  •  

                    265,193

                  • -46.72%

                  • 0.35

                  • AQR Capital Management LLC

                  •  

                    165,400

                  • -71.02%

                  • 0.22

                  • Merrill Lynch & Co Inc

                  •  

                    116,299

                  • +4,834.20%

                  • 0.15

                  • BlackRock Advisors LLC

                  •  

                    113,370

                  • -7.18%

                  • 0.15

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Core

                  GTx, Inc. is a Delaware corporation incorporated on September 24, 1997. It operates as a biopharmaceutical company dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathw...moreays to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical conditions. The Company develops selective androgen receptor modulators, or SARMs, to prevent and treat muscle wasting in patients with cancer and other musculoskeletal wasting or muscle loss conditions, including chronic sarcopenia (age related muscle loss). They are conducting the POWER 1 and POWER 2 (Prevention and treatment Of muscle Wasting in patients with cancER) pivotal Phase III clinical trials evaluating enobosarm for the prevention and treatment of muscle wasting in patients...more with advanced non-small cell lung cancer. The Company is developing GTx-758, an oral luteinizing hormone, or LH, inhibitor for the treatment of advanced prostate cancer. In preclinical in vitro and in vivo models, GTx-758 has demonstrated the potential to reduce testosterone to castrate levels without causing certain estrogen deficiency side effects such as bone loss and hot flashes. The Company’s most advanced product candidate, toremifene, is being developed for the prevention of bone fractures and treatment of other estrogen deficiency side effects of ADT in men with prostate cancer and for the prevention of prostate cancer in high risk men with high grade PIN. Additionally the company is developing Capesaris (GTx-758), an oral nonsteroidal selective estrogen receptor (ER) alpha agonist, for secondary hormonal therapy in men with metastatic castration resistant prostate cancer, or CRPC, and, potentially, as a primary treatment for advanced prostate cancer used in combination with androgen deprivation therapy, or ADT. It faces competition from many different sources, including commercial pharmaceutical and biotechnology enterprises, academic institutions, government agencies and private and public research institutions.lessless

                  Key People

                  Mr. Marc S. Hanover

                  COO/Founder/President/CEO

                  Mr. J.R. Hyde, III

                  Chairman of the Board/Director

                  Mr. Jason T. Shackelford

                  CFO/Controller/Other Corporate Officer/Chief Accounting Officer

                  Jeffrey G. Hesselberg

                  Vice President, Divisional

                  Henry P. Doggrell

                  General Counsel/Other Executive Officer/Secretary/Vice President

                  • GTx Inc

                  • 175 Toyota Plaza

                  • Memphis, TN 38103

                  • USA.Map

                  • Phone: +1 901 523-9700

                  • Fax: +1 901 844-8075

                  • gtxinc.com

                  Incorporated

                  1997

                  Employees

                  32

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: